Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
6
Expiration
Dec 24, 2026
DTE
41d
Moneyness
OTM
Intrinsic
$0.00
IBRX 6 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.05 | -28.57% | 10 | 126 |
| Nov 20, 2026 | 7d | $0.10 | -41.18% | 20 | 4,487 |
| Nov 27, 2026 | 14d | $0.35 | +52.17% | 11 | 1,648 |
| Dec 4, 2026 | 21d | $0.30 | +0.00% | 4 | 11 |
| Dec 11, 2026 | 28d | — | — | 0 | 7 |
| Dec 18, 2026 | 35d | $0.37 | +0.00% | 4 | 1,040 |
| Dec 24, 2026 | 41d | — | — | 0 | 1 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Mar 19, 2027 | 126d | $0.78 | +34.48% | 50 | 566 |
| Apr 16, 2027 | 154d | $0.80 | -13.98% | 2 | 6 |
| May 21, 2027 | 189d | $0.75 | +0.00% | 2 | 6 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.